Merck Serono, Lupin in emerging markets deal

The Merck Serono S.A. biopharmaceutical division of Merck KGaA (Xetra:MRK) partnered with Lupin Ltd. (NSE:LUPIN; BSE:500257) to develop and commercialize up to 20 general medicines in emerging markets. Lupin will develop and supply products to Merck Serono, which will hold marketing authorizations and commercialize the products.

Merck Serono said the deal will focus primarily on cardiovascular diseases and diabetes. The deal covers Latin America, Asia, central Eastern Europe and Africa, including major markets such as Brazil, Mexico, Indonesia and the Philippines, as well as undisclosed countries in Africa and central Eastern Europe. ...